Moderna Inc. has announced new clinical data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab for patients with checkpoint inhibitor-resistant or refractory (CPI-R/R) melanoma. Results from the study, which include clinical, safety, and translational data, will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, scheduled for October 17-21, 2025, in Berlin, Germany. The presentation, titled "Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma," will be delivered by Prof. David J. Pinato on October 17, 2025. mRNA-4359 is an investigational immune-evasion targeted cancer antigen therapy designed to encode epitopes of two immune escape pathways, PD-L1 and IDO1, with the aim of eliciting antigen-specific T cell responses. Moderna reports that mRNA-4359 in combination with pembrolizumab has shown a consistently manageable safety profile, with no new immune-related adverse events observed. The therapy continues to be evaluated in an ongoing Phase 1/2 trial for patients with advanced melanoma and non-small cell lung cancer.